Sociedad Americana de Hirudoterapia

Enzymatic production of specifically distributed hyaluronan oligosaccharides

Research article published in Carbohydr Polym (2015)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Farmacología salivalDesarrollo de fármacosYuan P et al. · Carbohydr Polym, 2015

Abstract

High-molecular-mass hyaluronan (HA) was controllably depolymerized in pure aqueous solution with recombinant leech hyaluronidase (HAase). The HAase concentration per unit HA and hydrolysis time played important roles in molecular mass distribution. By modulating the concentrations of HAase and controlling the hydrolysis time, any molar-mass-defined HA oligomers could be efficiently and specifically produced on a large scale (40 g/L), such as HA oligosaccharides with weight-average molar mass of 4000, 10,000, and 30,000Da and end hydrolysates containing only HA6 and HA4. High performance liquid chromatography-size exclusion chromatography, polyacrylamide gel electrophoresis, capillary zone electrophoresis, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry confirmed low polydispersity of the produced molar-mass-defined HA oligosaccharides. Therefore, large-scale production of defined HA oligosaccharides with narrow molecular mass distribution will significantly promote progress in related research and its potential applications.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsBiocatalysisChromatography, GelChromatography, High Pressure LiquidElectrophoresis, CapillaryElectrophoresis, Polyacrylamide GelEnzyme StabilityFermentationHyaluronic AcidHyaluronoglucosaminidaseHydrolysisLeeches

Resumen

Recombinant leech hyaluronidase produces molar-mass-defined HA oligomers (4000, 10000, 30000 Da) at 40 g/L; large-scale production for industrial applications.

Por qué esto importa para la hirudoterapia

This study demonstrated that recombinant leech hyaluronidase could controllably depolymerize high-molecular-mass hyaluronan in pure aqueous solution to efficiently produce molar-mass-defined hyaluronan oligosaccharides at large scale (up to 40 g/L), with multiple analytical techniques confirming low polydispersity of the products. The use of a leech-derived enzyme gives this work relevance to ASH's domain by contributing to the biochemical and biotechnological characterization of a leech enzyme. However, the study is purely biochemical and biotechnological in nature, using a recombinant enzyme rather than live leeches, and does not address hirudotherapy, clinical leech applications, or the broader leech secretome.

Citación

Enzymatic production of specifically distributed hyaluronan oligosaccharides.

Yuan P et al. · Carbohydr Polym, 2015

DOI

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Salivary Gland SecretionAnti-Inflammatory MechanismsSalivary ComplexDrug PipelineDrug DevelopmentDirect Thrombin InhibitorsOtolaryngology

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.